Olipass Corp
244460
Company Profile
Business description
Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.
Contact
16-4, 16 Beon-gil, Dongbaek Jungang-ro
Ace Dongbaek Tower 20th Floor
Giheung-gu
Yongin17015
KORT: +82 3180608200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
27
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,324.60 | 40.80 | 0.44% |
CAC 40 | 8,206.07 | 31.87 | 0.39% |
DAX 40 | 24,258.80 | 427.81 | 1.80% |
Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
FTSE 100 | 9,403.57 | 49.00 | 0.52% |
HKSE | 25,858.83 | 611.73 | 2.42% |
NASDAQ | 22,990.54 | 310.57 | 1.37% |
Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,735.13 | 71.12 | 1.07% |
S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
SSE Composite Index | 3,863.89 | 24.14 | 0.63% |